Home Cart Sign in  
Chemical Structure| 56932-43-5 Chemical Structure| 56932-43-5

Structure of NSC-87877 disodium
CAS No.: 56932-43-5

Chemical Structure| 56932-43-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

NSC 87877 is a cell-permeable inhibitor of both SHP-1 and SHP-2 with IC50 values of 355 and 318 nM respectively. It also inhibits EGF-induced Erk1/2 activation in HEK293 cells and significantly reduces MDA-MB-468 cell viability/proliferation.

Synonyms: NSC 87877

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of NSC-87877 disodium

CAS No. :56932-43-5
Formula : C19H11N3Na2O7S2
M.W : 503.42
SMILES Code : O=S(C1=C2C=CC=NC2=C(O)C(/N=N/C3=CC=C4C=C(S(=O)([O-])=O)C=CC4=C3)=C1)([O-])=O.[Na+].[Na+]
Synonyms :
NSC 87877
MDL No. :MFCD00041863
InChI Key :IFVGQKHFUZRWNA-UHFFFAOYSA-L
Pubchem ID :92576

Safety of NSC-87877 disodium

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Human dermal fibroblasts 100 μM 6 hours To investigate the effects of NSC-87877 on TGF β-induced STAT3 signaling, results showed that NSC-87877 inhibited STAT3-dependent reporter activity. PMC6092362
Human dermal fibroblasts 100 μM 24 hours To investigate the effects of NSC-87877 on TGF β-induced fibroblast activation, results showed that NSC-87877 reduced COL1A1 mRNA levels and collagen protein release. PMC6092362
Primary mouse hepatocytes 10 μM 24 hours To evaluate the effect of NSC-87877 on NR4A1 signaling, results showed that NSC treatment increased NR4A1 serine phosphorylation (pNR4A1S351) and altered its subcellular localization. PMC9462473
Hu1545 cells 1 μM 24 hours To evaluate the effect of NSC-87877 on YAP signaling, results showed that NSC treatment increased YAP tyrosine phosphorylation (pYAPY357) and promoted YAP nuclear localization and transcriptional activity. PMC9462473
SH-SY5Y 0.5 μM 5 days To test the effects of NSC-87877 on neuroblastoma cell proliferation, results showed a more pronounced decrease in proliferation at 0.5 μM in NB-19 and SH-SY5Y cell lines. PMC4558500
NB-19 0.5 μM 5 days To test the effects of NSC-87877 on neuroblastoma cell proliferation, results showed a more pronounced decrease in proliferation at 0.5 μM in NB-19 and SH-SY5Y cell lines. PMC4558500
IMR32 0.25 μM 5 days To test the effects of NSC-87877 on neuroblastoma cell proliferation, results showed a decrease in proliferation by day 5 at 0.25 μM in all cell lines. PMC4558500
HL-60 cells differentiated into monocytes 50 μM 15 minutes NSC-87877 restored STAT3 phosphorylation and prevented the TNFα-induced inhibition of IL-10 signaling. PMC10539668
Human monocytes 50 μM 15 minutes NSC-87877 restored STAT3 phosphorylation and prevented the TNFα-induced inhibition of IL-10 signaling. PMC10539668
2C CD8+ T cells 150 μM 4 days To evaluate the effect of NSC-87877 on T-cell proliferation, results showed a 3.4-fold expansion in T-cell numbers in ShpI-supplemented cultures. PMC3395588
MA-10 Leydig cells 50 µM 3 hours NSC87877 inhibited the 8Br-cAMP-stimulated increase in ACSL4 protein levels and progesterone production. PMC3196225
MDA-MB-231 breast cancer cells 50 µM 24 hours NSC87877, a specific inhibitor of the tyrosine phosphatase SHP2, reduced ACSL4 protein levels in MDA-MB-231 cells. PMC3196225
C2C12 mouse myotubes 100 μg 2.5 hours NSC-87877 increased the number of microclusters and led to fully formed AChR clusters. PMC10427144

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Bleomycin-induced skin fibrosis model Intraperitoneal injection 5 mg/kg/day Once daily for 3 weeks To investigate the effects of NSC-87877 on bleomycin-induced skin fibrosis, results showed that NSC-87877 reduced dermal thickness, hydroxyproline content, and myofibroblast counts. PMC6092362
C57BL/6J mice 70% partial hepatectomy model Intraperitoneal injection 7.5 mg/kg/dose, twice daily Starting 1 day preoperatively and every 12 hours postoperatively until euthanasia To evaluate the effect of NSC-87877 on liver regeneration, results showed that NSC treatment accelerated liver regeneration, reduced liver injury markers (e.g., ALT), and improved postoperative survival in a nonalcoholic steatohepatitis (NASH) model. PMC9462473
Female nude mice Intrarenal neuroblastoma model Intraperitoneal injection 30 mg/kg Once daily for 15 days To test the effects of NSC-87877 on neuroblastoma tumor growth in vivo, results showed significantly decreased tumor growth in the treatment group and increased p53 and p38 activity. PMC4558500
BALB/c mice Collagen antibody-induced arthritis (CAIA) model Intraperitoneal injection 30 mg/kg Daily for 8 days (except on day 3–5) NSC-87877 dampened inflammation in the collagen antibody-induced arthritis (CAIA) mouse model. PMC10539668
C57BL/6 mice Experimental autoimmune encephalomyelitis (EAE) Intraperitoneal injection 2.5 mg/kg Daily from the day of immunization onward To evaluate the therapeutic effect of NSC-87877 on EAE, results showed NSC-87877 significantly delayed disease onset and reduced EAE severity, almost completely abolishing EAE development. PMC3966750
Mice Unilateral cortical injury model Intra-cortical injection 200 μM Continuously for 14 days Suppression of SHP-1 activity promotes corticospinal tract axonal sprouting and functional recovery PMC3641325

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.99mL

0.40mL

0.20mL

9.93mL

1.99mL

0.99mL

19.86mL

3.97mL

1.99mL

References

 

Historical Records

Categories